Dare Bioscience (NASDAQ:DARE) Now Covered by Analysts at Maxim Group

Maxim Group began coverage on shares of Dare Bioscience (NASDAQ:DARE) in a research note released on Monday morning, TipRanks reports. The brokerage issued a buy rating and a $3.00 price objective on the biotechnology company’s stock.

Several other brokerages also recently weighed in on DARE. ValuEngine raised Dare Bioscience from a hold rating to a buy rating in a report on Tuesday, July 2nd. Aegis initiated coverage on Dare Bioscience in a research note on Thursday, August 22nd. They set a buy rating on the stock.

Shares of DARE traded up $0.01 during midday trading on Monday, hitting $0.81. 250,552 shares of the company’s stock traded hands, compared to its average volume of 563,616. The stock has a market capitalization of $13.51 million, a price-to-earnings ratio of -0.74 and a beta of 1.89. Dare Bioscience has a 1 year low of $0.60 and a 1 year high of $3.25. The firm’s fifty day moving average is $0.78 and its 200-day moving average is $0.95.

Dare Bioscience (NASDAQ:DARE) last announced its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.09). As a group, research analysts expect that Dare Bioscience will post -0.88 EPS for the current fiscal year.

A hedge fund recently raised its stake in Dare Bioscience stock. Geode Capital Management LLC raised its stake in shares of Dare Bioscience Inc (NASDAQ:DARE) by 80.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 105,470 shares of the biotechnology company’s stock after purchasing an additional 47,170 shares during the quarter. Geode Capital Management LLC owned about 0.92% of Dare Bioscience worth $73,000 at the end of the most recent reporting period. 5.11% of the stock is owned by institutional investors.

About Dare Bioscience

Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder.

Further Reading: Outstanding Shares

Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.